The newly retracted paper, “rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis,” has not yet been cited, according to Thomson Reuters Web of Science.
Here’s the retraction note, which tells us a bit more:
The above article, published online on 28th November 2015 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1111/bcp.12788/full), and in volume 81, pp. 174–185, has been retracted by agreement between the authors, the journal Editor in Chief, Professor A Cohen, and John Wiley & Sons Limited. The retraction has been agreed owing to evidence indicating that the peer review of this paper was compromised. The authors were unaware of the actions of the third party responsible for compromising the peer review.
Xiao-Feng Long, last author of the paper from Dalian University in China, told us the third party involved with processing the manuscript is a company called “EditPub.” Long added the authors were “shocked” by what happened:
We are very sad and regret that our own academic achievements have lost the opportunity to publish in British Journal of Clinical Pharmacology.
Long said the team was still confident in the paper:
Of course, we firmly believe…the authenticity of our academic results, the reason for our loss of the publishing opportunity might be closely correlated with the ability of our lacking of adequate academic study ability, rather than the so-called academic fraud. We therefore make up our mind not to give up our research and try our best to improve our academic research ability.
Adam Cohen, editor-in-chief of BJCP and chief executive officer of the Centre for Human Drugs Research at Leiden in the Netherlands, told us he plans to publish an editorial titled, “Organised crime against peer review,” which will give “the full picture” and reveal “all names” of parties involved with the case. Cohen, however, declined to comment on the specifics until the editorial is published.
We’ve contacted EditPub for a comment, and will update the post if we hear back.
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our new daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here.